YUAN, SHYNG SHIOU,袁行修,袁行修,WU, YANG CHANG,吴永昌,吳永昌,CHANG, HSUEH LING,张雪玲,張雪玲,CHANG, FANG RONG,张芳荣,張芳榮
申请号：
TW097134287
公开号：
TWI394568B
申请日:
2008.09.05
申请国别(地区):
TW
年份:
2013
代理人:
摘要：
A pharmaceutical composition, composed of protoapigenone (formula I), for treating gynecological cancers, prostate cancer, urinary bladder cancer and hepatocarcinoma is provided. Protoapigenone has cytotoxicity on these cancers, and arrests the cell cycle on S and G2/M phases. In addition, protoapigenone regulates cell signaling pathways, such as caspase-3, PARP, p-38 MAPK and JNK1/2, to induce apoptosis. Protoapigenone significantly inhibits the xenograft tumor growth of nude mice, without major side effects. Co-treatment of protoapigenone and cisplatin shows synergistic cytotoxicity of MADH-2774 ovarian cancer cells.本發明係提供一種治療婦科癌症、前列腺癌、膀胱癌及肝癌之藥物組合物,其具有如式I的黃酮類化合物。該黃酮類化合物具有毒殺癌細胞的活性,並藉由調控癌細胞之細胞週期蛋白,將癌細胞停滯於S及G2/M週期。此外,該黃酮類化合物調控caspase-3、PARP、p-38MAPK、JNK1/2等訊息傳導路徑誘導細胞凋亡。該黃酮類化合物能有效的抑制裸鼠之異體移植癌細胞,而沒有副作用。該黃酮類化合物與順鉑對癌細胞具有加成毒殺作用。
